Enterprise Revenue Advisory · B2B

You don't necessarily have a sales problem. You have an undiagnosed one.

Missing the number is a symptom. The cause is usually a step away from where everyone is looking — and the plan you've already written is aimed at the wrong one.

I diagnose why revenue isn't compounding, then fix the two or three things that actually move it.

You get a revenue health score, the stage you're really in, and which of the three directions needs calibration. Free, and the full report is yours — no commitment attached to it.

How you tell: split win rate by segment. If the best segment converts more than twice as well as the worst, you don't have one pipeline — you have two, and one is eating the other's capacity.
How you tell: plot churn against days-to-first-value per account. If the accounts that leave are the ones that took longest to get going, the leak is in onboarding, not in the renewal conversation.
How you tell: compare win rate on deals you personally worked against deals you didn't. A wide gap isn't a hiring problem — it's a motion that only exists in your head.
How you tell: ask whether your last ten wins look like each other. If they don't, you're scaling a motion you haven't found yet, and more spend makes it worse rather than better.

Each right-hand answer is a candidate, not a verdict — which is exactly why it needs testing. Select any row for the test that separates the two.

The expensive mistakes

Treating the wrong problem doesn't fail loudly. It fails slowly.

If the real constraint is retention and you spend the quarter on pipeline, nothing breaks. You hit more meetings, you report progress, the board is satisfied — and two quarters later you're further behind than when you started, having done everything you said you'd do.

A wrong plan is executed competently and defended by everyone who built it. That's what makes a misdiagnosis worse than inaction: you don't lose the argument, you lose the quarters.

Diagnose

the problem — every lever rated red, amber or green, before anything gets prescribed.

Clarify

with evidence from your numbers, your voices and your systems. No unsupported opinions.

Prioritize

and fix the two or three opportunities that actually move the number, in the right order.

Diagnose broad, treat specific.

Where growth actually comes from

Three directions. One of them is your constraint.

Two things sit underneath all of it — whether you're clear on who you're for, and whether the business can win without you in the room. If either is broken, everything above it is noise. Each direction then breaks apart into the specific levers that decide it.

Pipeline creation
Is enough of the right pipeline being built?
Qualified pipeline $ / coverage ratio
Win rate
Does pipeline advance and convert?
Stage-to-stage conversion, overall win rate
Velocity
How long does a deal actually take?
Sales cycle length by segment
ACV
Are you charging what it's worth?
Average contract value, discount rate
Gross revenue retention
Are you keeping what you sold?
GRR, logo churn, dollar churn
Time-to-value
How fast do they get the outcome they bought?
Days to first value / to full activation
Engagement & adoption
Are they actually using it?
Usage depth, exec sponsor activity
Net revenue retention
Is the base growing on its own?
NRR
Upsell
More seats, volume, higher tier?
Expansion ARR from existing SKUs
Cross-sell
Are adjacent products landing?
Multi-product attach rate
Account whitespace
How much room is left?
Penetration vs. account ceiling

The order matters more than the effort

Filling a leaking bucket is the most expensive mistake at this stage.

It's also the most common, because the leak is quiet and the tap is visible. Pipeline has a dashboard. Churn shows up a year later, in someone else's quarter.

Retention → Expansion → New Business

Retention first, because it makes everything you've already acquired worth more. A point of gross retention doesn't save that revenue once — it compounds against every cohort you already have and every one you add next.

Expansion second, because it's the cheapest revenue you have. Acquisition is already sunk, the trust already exists, the cycle is a fraction of a new logo's — and it moves NRR, which is the number your next round gets priced on.

New business last, because it's the easiest to over-commit to. Scaling acquisition into a system that leaks buys revenue that walks straight out the other end, and you find out two quarters after you've hired against it.

When this order is wrong — and sometimes it is
  • Your retention is already strong. Gross retention at 90%+ and healthy by cohort means there's nothing to fix. Go straight to expansion or new business.
  • Runway makes new logos existential. If you need bookings this quarter to still be here next year, retention work that pays off in three quarters is the wrong prescription. We'd sequence for the constraint you actually have.
  • The churn is in a segment you're leaving anyway. That's not a retention problem, it's an ICP problem wearing its coat.
  • The fix is a product rebuild, not a go-to-market change. No sales motion solves that, and the sequence has to be built around it rather than over it.

Before any of the directions

You may be one stage earlier than you think

The first three are gates, not phases — you don't get to optimise the directions until you're through them. Most of the wasted quarters I've seen went into scaling a motion the company hadn't actually found yet.

ICP definition

The question being answered: Who is this actually for?

Dominant failure mode: Selling to anyone who'll take a meeting.

Select a stage to see what it's really asking. The assessment tells you which one you're in.

The part that changes the answer

Your customers won't tell you this. They'll tell me.

Part of the diagnosis is impossible to run from inside. I call 3–5 of your current customers, 2–3 who churned, and 2–3 prospects who chose someone else — on my own, with nobody from your team on the line, and their quotes come back unattributed.

A customer won't tell the founder what they really think of onboarding. A churned account gives your CSM a polite non-reason and gives an outsider the real one. And the prospect who picked your competitor won't take the call from the rep who lost them — but will take it from someone who isn't selling anything, and will say exactly what your competitor said that landed.

That's not a matter of being better at interviewing. It's who's asking.

What you walk away with

Revenue Health Scorecard
Red, amber or green on every lever, each with the evidence behind the rating.
Prioritized Opportunity Map
The two or three highest-leverage fixes, sized and plotted against effort. This is the one your board sees.
90-Day Action Roadmap
What to do, in what order, who owns it, and what good looks like at day 30, 60 and 90.

Yours to keep.

Leor Teichmann

Who actually does the work

Leor Teichmann

I have personally moved the numbers this assessment measures — first commercial hire in North America at Trax, $0 to $40M+; a GTM built from zero at Harmonya, 5× revenue in two years at 140% NRR. I come with agents, not a team of people, which is what lets the analysis go wider than one person could take it, while the person who reaches the conclusion is still the person who presents it to you.

Start here

Find out which direction needs calibration

The Northlight Compass — a revenue health assessment. You get a score, a read on which stage you're really in, a side-by-side of your three directions, and written findings on what your answers say in combination. Free, and nothing in it is held back.